← The Wire
NTLANasdaq
Intellia Therapeutics, Inc.
In Vitro & In Vivo Diagnostic Substances · DE · CIK 1652130
Intellia Therapeutics revolutionizes medicine by developing curative CRISPR gene editing treatments for severe diseases
⚡ Elevated coverage
$1.69B
Market cap
$16.61
Last close
-0.4%
1D
+5.5%
5D
5.6M
Volume
Price · last 39 sessions+19.8%
May 4L $11.94 · H $16.68Jun 29
229
Total filings
Jun 15, 2026
Last filing
12/31
Fiscal year end
8-KReg FD Disclosure · Company UpdateJun 15, 20268-KShareholder VoteJun 10, 202610-Q10-QMay 11, 20268-KResults of OperationsMay 11, 20268-KMaterial Agreement · Results of OperationsApr 30, 2026DEFA14ADEFA14AApr 30, 2026DEF 14ADEF 14AApr 30, 2026424B5424B5Apr 29, 2026424B5424B5Apr 27, 20268-KReg FD Disclosure · Company UpdateApr 27, 20268-KBylaw AmendmentApr 10, 2026424B5424B5Mar 2, 20268-KMaterial Agreement · Reg FD DisclosureMar 2, 202610-K10-KFeb 26, 20268-KResults of OperationsFeb 26, 20268-KReg FD Disclosure · Company UpdateJan 27, 20268-KReg FD Disclosure · Company UpdateJan 9, 20268-KReg FD Disclosure · Company UpdateNov 10, 202510-Q10-QNov 6, 20258-KResults of OperationsNov 6, 20258-KCompany UpdateOct 29, 20258-KReg FD Disclosure · Company UpdateOct 27, 20258-KReg FD Disclosure · Company UpdateSep 25, 202510-Q10-QAug 7, 20258-KExecutive Change · Results of OperationsAug 7, 20258-KReg FD Disclosure · Company UpdateJun 16, 20258-KExecutive Change · Shareholder VoteJun 12, 20258-KReg FD Disclosure · Company UpdateMay 28, 20258-KReg FD Disclosure · Company UpdateMay 19, 202510-Q10-QMay 8, 20258-KResults of OperationsMay 8, 2025DEFA14ADEFA14AApr 30, 2025DEF 14ADEF 14AApr 30, 20258-KBylaw AmendmentApr 7, 202510-K10-KFeb 27, 20258-KResults of OperationsFeb 27, 20258-KMaterial Agreement · New Debt / ObligationFeb 21, 20258-KExecutive Change · Results of OperationsJan 10, 20258-KReg FD Disclosure · Company UpdateNov 18, 202410-Q10-QNov 7, 20248-KResults of OperationsNov 7, 20248-KReg FD Disclosure · Company UpdateOct 25, 202410-Q10-QAug 8, 20248-KResults of OperationsAug 8, 20248-KExecutive Change · Reg FD DisclosureJun 26, 20248-KExecutive Change · Reg FD DisclosureJun 14, 20248-KBylaw Amendment · Shareholder VoteJun 13, 202410-Q10-QMay 9, 20248-KResults of OperationsMay 9, 2024DEFA14ADEFA14AApr 29, 2024DEF 14ADEF 14AApr 29, 20248-KExecutive ChangeApr 15, 20248-KAgreement TerminatedMar 22, 2024424B5424B5Feb 26, 2024424B5424B5Feb 23, 20248-KMaterial AgreementFeb 23, 202410-K10-KFeb 22, 20248-KResults of OperationsFeb 22, 20248-KReg FD DisclosureFeb 1, 20248-KResults of Operations · Reg FD DisclosureJan 4, 20248-KExecutive ChangeDec 6, 202310-Q10-QNov 9, 20238-KResults of OperationsNov 9, 20238-KReg FD Disclosure · Company UpdateNov 2, 20238-KReg FD Disclosure · Company UpdateOct 18, 20238-KReg FD Disclosure · Company UpdateOct 3, 202310-Q10-QAug 3, 20238-KResults of OperationsAug 3, 20238-KBylaw Amendment · Shareholder VoteJun 16, 20238-KReg FD Disclosure · Company UpdateJun 12, 2023DEFA14ADEFA14AJun 5, 20238-KExecutive Change · Reg FD DisclosureJun 5, 202310-Q10-QMay 4, 20238-KResults of OperationsMay 4, 2023DEFA14ADEFA14AMay 1, 2023DEF 14ADEF 14AMay 1, 20238-KExecutive Change · Reg FD DisclosureApr 17, 20238-KExecutive ChangeMar 24, 20238-KCompany UpdateMar 2, 202310-K10-KFeb 23, 2023
Insider Activity
In the 90 days to Mar 2, 2026: 1 insider bought $1.4M · 7 sold $1.6M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Basta JamesEVP, General Counsel | Sell | 1,211 | $13.78 | $17K |
| Mar 2, 2026 | Clark ElianaEVP, Chief Technical Officer | Sell | 607 | $13.78 | $8K |
| Jan 5, 2026 | Cohen Fred EDirector | Buy | 150,000 | $9.35 | $1.4M |
| Jan 5, 2026 | Leonard John MPresident and CEO | Sell | 34,146 | $9.21 | $314K |
| Jan 5, 2026 | Lebwohl DavidEVP, Chief Medical Officer | Sell | 11,903 | $9.21 | $110K |
| Jan 5, 2026 | Basta JamesEVP, General Counsel | Sell | 10,397 | $9.21 | $96K |
| Jan 5, 2026 | Clark ElianaEVP, Chief Technical Officer | Sell | 9,515 | $9.21 | $88K |
| Jan 5, 2026 | Schultes Birgit CEVP, Chief Scientific Officer | Sell | 8,508 | $9.21 | $78K |
| Jan 5, 2026 | Dulac Edward J IiiEVP, Chief Financial Officer | Sell | 6,379 | $9.21 | $59K |
| Jan 5, 2026 | Dube Michael PVP, Chief Accounting Officer | Sell | 2,989 | $9.21 | $28K |
| Dec 11, 2025 | Leonard John MPresident and CEO | Sell | 49,959 | $9.49 | $474K |
| Dec 11, 2025 | Leonard John MPresident and CEO | Sell | 32,832 | $9.47 | $311K |
| Dec 11, 2025 | Leonard John MPresident and CEO | Sell | 5,355 | $9.59 | $51K |
| Oct 1, 2025 | Dube Michael PVP, Chief Accounting Officer | Sell | 1,871 | $17.38 | $33K |
| Oct 1, 2025 | Schultes Birgit CEVP, Chief Scientific Officer | Sell | 31 | $17.38 | $539 |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 1 reputable article · skews ▲ positive.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance